While the discrepancy between the success of the drug and genetic inference might be explained by the rather weak affinity of baricitinib for TYK233, patients undergoing trials with TYK2-inhibitors for psoriasis34 might be at an elevated risk for severe COVID-19. Here, TYK2 is linked to COVID-19.